Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBIT (2020 - 2025)

Historic EBIT for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $223.2 million.

  • Apellis Pharmaceuticals' EBIT rose 57204.53% to $223.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.4 million, marking a year-over-year increase of 13600.26%. This contributed to the annual value of -$165.0 million for FY2024, which is 6809.66% up from last year.
  • Apellis Pharmaceuticals' EBIT amounted to $223.2 million in Q3 2025, which was up 57204.53% from -$33.3 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' EBIT ranged from a high of $223.2 million in Q3 2025 and a low of -$194.3 million during Q2 2021
  • In the last 5 years, Apellis Pharmaceuticals' EBIT had a median value of -$120.4 million in 2023 and averaged -$89.8 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' EBIT tumbled by 16870.89% in 2021, and later skyrocketed by 57204.53% in 2025.
  • Apellis Pharmaceuticals' EBIT (Quarter) stood at -$89.4 million in 2021, then plummeted by 83.5% to -$164.1 million in 2022, then skyrocketed by 48.48% to -$84.5 million in 2023, then skyrocketed by 69.04% to -$26.2 million in 2024, then skyrocketed by 953.02% to $223.2 million in 2025.
  • Its last three reported values are $223.2 million in Q3 2025, -$33.3 million for Q2 2025, and -$83.3 million during Q1 2025.